WELL

Welltower

$234.60

+0.61%
Oct 30, 2026
Bobby Quantitative Model
Welltower Inc. is a real estate investment trust that owns a diversified healthcare real estate portfolio of roughly 2,950 in-place properties spanning senior housing, medical office, and skilled nursing/post-acute care, with over 900 properties in Canada and the United Kingdom alongside its U.S. base. The company is the dominant consolidator in senior housing operating (SHO) real estate, distinguished less by passive rent collection than by an operator-partnership model that captures senior housing operating leverage as occupancy and pricing recover. The current investor narrative centers on an aggressive external growth campaign — quarterly acquisition outlays of $5.2 billion in Q2 2026 alone, funded partly by $2.9 billion of equity issuance — layered on top of a 40.9% year-over-year revenue surge, which bulls frame as a demographic-driven compounding story and skeptics view as a capital-intensive bet priced for perfection. Debate also hinges on the interest-rate backdrop for REITs and whether the company's very low reported GAAP earnings (EPS of $0.0076) reflect depreciation and acquisition accounting rather than underlying cash economics.

People also watch

Ventas, Inc.

Ventas, Inc.

VTR

Analysis
Healthpeak Properties

Healthpeak Properties

DOC

Analysis
Omega Healthcare Investors Inc.

Omega Healthcare Investors Inc.

OHI

Analysis
American Healthcare REIT, Inc.

American Healthcare REIT, Inc.

AHR

Analysis
CareTrust REIT, Inc

CareTrust REIT, Inc

CTRE

Analysis

WELL 12-Month Price Forecast

Historical Price
Current Price $234.60
Average Target $234.60
High Target $269.79
Low Target $199.41

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Welltower's 12-month outlook, with a consensus price target around $260.71 and implied upside of +11.1% versus the current price.

Average Target

$260.71

0 analysts

Implied Upside

+11.1%

vs. current price

Analyst Count

—

covering this stock

Price Range

$219 - $292

Analyst target range

Coverage is deep and constructive: 22 analysts cover Welltower with a consensus recommendation of "buy" and a recommendation mean of 1.64 (where 1.0 is a strong buy), and the average target price of $260.55 implies +9.8% upside from the current $237.32. Consensus estimates call for EPS of $5.80 (range $5.38-$6.16) on average revenue of $29.99 billion (range $28.32-$31.44 billion), which implies continued double-digit top-line expansion from the current run-rate. The bullish tilt is notable given the stock already trades near its 52-week high, suggesting analysts see further re-rating or earnings delivery ahead rather than mean reversion.

The target range of $219.00 to $292.00 is moderately wide — roughly 33% from low to high — signaling meaningful dispersion in assumptions about acquisition pacing, cost of capital, and SHO occupancy recovery. The $292 high target likely assumes continued cap-rate spread investing, accelerating senior housing occupancy, and multiple expansion toward premium REIT peers; the $219 low target, only -7.7% below the current price, prices in margin compression, higher financing costs, or a slowdown in external growth. Institutional ratings show a mixed recent pattern: JP Morgan downgraded to Neutral from Overweight in December 2025, while Evercore ISI upgraded to Outperform in November 2025 and Wells Fargo, RBC, Wedbush, and Jefferies all moved to Buy/Outperform/Overweight during 2025 — a net-positive drift with one notable caution flag. The tight downside to the low target versus the wider upside to consensus suggests a favorably skewed risk/reward, though the stock's premium valuation means the margin of safety rests on execution rather than price.

Drowning in data?

Find the real signal!

WELL Technical Analysis

Welltower is in a sustained uptrend, with a 1-year price change of +34.8% and a YTD gain of +26.9%, both far ahead of the S&P 500's +13.1% and +11.5% over the same windows. At $237.32, the stock sits at roughly 92.9% of its 52-week range of $174.91 to $255.20 — near the upper end but not at the highs, which signals durable momentum rather than an overextended blow-off top. The relative strength of +21.7 percentage points versus SPY over one year confirms genuine leadership, though the failure to reclaim the July high of $255.20 leaves a visible ceiling overhead.

Short-term momentum is constructive but decelerating: the stock is up +3.24% over the past month (versus SPY's -1.02%, a +4.26 point relative gain) yet down -5.85% over three months, a stark -8.70 point relative underperformance against a market that rose +2.85%. That divergence — a strong 12-month trend interrupted by a three-month pullback and now a one-month bounce — is characteristic of a consolidation phase rather than a trend reversal, with the October recovery from the $221.12 low on October 7 suggesting buyers are defending the $220s. The 180-day price series shows a clear July peak near $252 followed by a choppy August-September range of roughly $226-$241, and the recent push back to $237.32 places the stock mid-range with improving short-term breadth.

Key technical levels are well defined: support sits at the 52-week low of $174.91, with a nearer tactical floor at the October low of $221.12 and the August dip to $226.01; resistance is the 52-week high of $255.20, with the July closing peak of $252.07 as the immediate barrier. A breakout above $255 would confirm resumption of the primary uptrend and likely trigger momentum-driven buying, while a breakdown below $221 would break the higher-lows structure and target the $200 area. With a beta of 0.747, Welltower is roughly 25% less volatile than the market, and its max drawdown of -12.61% over the period is modest for a REIT — supportive of larger position sizing but also implying that rate-driven shocks, not equity beta, are the dominant risk factor.

Beta

0.75

0.75x market volatility

Max Drawdown

-12.6%

Largest decline past year

52-Week Range

$178-$255

Price range past year

Annual Return

+29.7%

Cumulative gain past year

PeriodWELL ReturnS&P 500
1m+1.9%-0.9%
3m+0.1%+1.2%
6m+8.2%+4.9%
1y+29.7%+11.2%
ytd+25.5%+10.8%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

WELL Fundamental Analysis

Revenue is growing at an exceptional pace for a REIT: Q2 2026 revenue of $3.545 billion rose 40.9% year over year from $2.516 billion in Q2 2025, extending a streak from $3.306 billion in Q1 2026 and $3.134 billion in Q4 2025. The growth is overwhelmingly organic-plus-acquired senior housing: resident fees and services contributed $2.985 billion of the quarter's revenue versus $460 million of rental income and $77 million of interest income, meaning the SHO segment drives roughly 84% of the top line. The trajectory is clearly accelerating rather than decelerating, but investors should recognize that a meaningful share reflects portfolio acquisitions ($5.2 billion in Q2 alone) rather than same-store growth, which raises the bar for future comparisons.

Profitability is thin on a GAAP basis but improving operationally: Q2 2026 net income was $240.3 million (net margin 6.8%) on gross margin of 39.3%, with operating income of $589.2 million and an operating margin of 16.6%. Gross margin has been remarkably stable in a 37.8%-39.9% band over the past six quarters, while EBITDA rose to $1.327 billion (37.4% EBITDA margin) from $948 million a year earlier. The Q1 2026 net income of $728.7 million was inflated by a $205.5 million non-operating gain and a low 1.5% effective tax rate, so the Q2 figure is the cleaner read — and the Q4 2025 GAAP operating loss of -$943.7 million (driven by a $1.56 billion SG&A charge) illustrates how acquisition and compensation accounting can distort headline earnings for this REIT.

Balance sheet and cash generation are adequate but capital-hungry: debt-to-equity is 0.507, total debt-to-capitalization is roughly 29.8%, and the current ratio of 5.34 reflects a $2.10 billion cash balance against modest short-term liabilities. TTM free cash flow is $2.662 billion, but quarterly FCF is volatile ($881 million in Q2 2026 versus $282 million in Q1) because of heavy capex ($319 million in Q2) and acquisition spending, and dividends paid of $524 million in Q2 exceed the $240 million of net income — a payout ratio of 2.00 on earnings that is only covered by cash flow, not GAAP profit. ROE of 2.22% and ROA of 0.83% are low in absolute terms, typical of a capital-intensive REIT but also a reminder that returns depend on spread investing — borrowing and issuing equity at yields below acquisition cap rates — rather than on high returns on existing assets.

Quarterly Revenue

$3.5B

2026-06

Revenue YoY Growth

+40.9%

YoY Comparison

Gross Margin

39.3%

Latest Quarter

Free Cash Flow

$2.7B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Resident fees and services
Rental income
Interest income
Other income

Open an Account, get $2 TSLA now!

Valuation Analysis: Is WELL Overvalued?

Because trailing net income is positive but negligible (EPS of $0.0076, net margin 8.8%), the trailing PE of 131.6x is economically meaningless and I therefore lead with the price-to-sales ratio of 11.58x and EV/EBITDA of 60.5x, cross-checked against the forward PE of 74.2x. The enormous gap between trailing PE (131.6x) and forward PE (74.2x) implies the market expects earnings to nearly double, consistent with consensus EPS of $5.80 versus the current run-rate, though even the forward multiple is extreme for a REIT. The P/FFO-style lens is more relevant: price-to-free-cash-flow of 42.9x and EV/Sales of 14.9x both sit at the high end of large-cap REIT valuations.

Against the REIT-healthcare facilities peer group, Welltower trades at a pronounced premium: a PS ratio of 11.58x and EV/EBITDA of 60.5x compare with typical healthcare REIT multiples in the mid-to-high teens on EV/EBITDA and low-to-mid single digits on sales, implying a premium of well over 100% on EV/EBITDA. That premium is partly justified by superior growth (+40.9% revenue YoY versus the low-to-mid single-digit same-store growth typical of the sector), the SHO operating model's higher margin capture, and the company's scale and cost of capital advantage as the sector consolidator. However, a 60.5x EV/EBITDA multiple leaves little room for execution error, and the negative PEG ratio of -12.23 reflects the mismatch between GAAP earnings and growth expectations.

Historically, Welltower's own valuation band has expanded dramatically: PS ratio was 20.99x in Q4 2022, 28.81x in Q4 2023, 35.53x in Q4 2024, and 40.84x in Q4 2025, with the current 11.58x reading reflecting a different share-count/revenue base in the provided data but the historical series clearly showing a multi-year re-rating. The price-to-book ratio has climbed from 1.56x in Q4 2022 to 2.93x today, and the dividend yield has compressed from 0.94% in Q4 2022 to 1.52% now (versus 0.33%-0.44% in the 2025 quarterly snapshots), evidence that the market has progressively paid more for the same assets. Trading near the top of its own historical valuation band means optimistic expectations are priced in — a value opportunity only if the acquisition-driven growth engine keeps compounding at current rates.

PE

131.6x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 43x~172x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

60.5x

Enterprise Value Multiple